Von Eschenbach to China
This article was originally published in The Tan Sheet
Executive Summary
FDA Commissioner Andrew von Eschenbach and Deputy Commissioner for International and Special Programs Murray Lumpkin met with China's minister of health and commissioner of China's food and drug agency as the two countries try to finalize a memorandum of agreement on the import safety of food, drugs and medical devices (1"The Tan Sheet" Aug. 20, 2007, p. 14). While withholding details of the MOA, Lumpkin noted that FDA's "preference is obviously not to have to catch problems in the products at our borders ... but prevent them at the source of their manufacturer." Von Eschenbach suggested the MOA will be finalized in early December, in time for HHS Secretary Mike Leavitt's visit to China. The meeting in Shanghai is the latest effort from the Bush administration's Interagency Working Group on Import Safety established in July...
You may also be interested in...
China Commits To Tightening Food Safety Supervision As MOA Talks Begin
A spokesman at the Chinese embassy in Washington says China will intensify its food safety supervision as U.S. and Chinese officials in Beijing begin work on a memorandum of agreement on food and feed safety
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.